12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Custirsen sodium: Phase III ongoing

OncoGenex said an IDMC recommended continuation of the open-label, international Phase III SYNERGY trial of weekly 640 mg IV custirsen following an interim efficacy analysis. The trial, which completed enrollment of 1,023 patients, is comparing custirsen plus docetaxel/prednisone vs. docetaxel/prednisone....

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >